72
Participants
Start Date
November 1, 2018
Primary Completion Date
March 24, 2019
Study Completion Date
March 29, 2019
Rapastinel
During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
Ketamine
"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
Placebo
"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
Vince and Associates Clinical Research Inc, Overland Park
Naurex, Inc, an affiliate of Allergan plc
INDUSTRY